Lexaria Bioscience Fact Sheet

LEXARIA BIOSCIENCE CORP. NASDAQ: LEXX DRUG DELIVERY PLATFORM INNOVATOR Market Value of 2022 DehydraTECH Investigations Planned pharmacokinetic (“PK”) studies will evaluate DehydraTECH’s ability to improve quantity of drug delivered and speed with which it is delivered, in all of these areas: Size Future Size DehydraTECH Markets US $bn Year US $bn Year Tobacco 786.1 2022 908.3 2026 Nicotine Replacement 59.8 2022 147.9 2028 CBD 4.1 2022 111.8 2030 Cardiovascular Drugs 96.1 2022 107.8 2025 Antivirals 55.6 2022 66.7 2025 Epilepsy 10.6 2021 16.6 2031 Human Hormones 5.4 2022 13.0 2026 PDE5 Inhibitors 4.9 2022 6.0 2025 Vitamin D3 1.2 2022 1.7 2026 LEXARIA SUBSIDIARIES Lexaria Nicotine LLC (Majority-Owned) • Altria Group international license rights for undisclosed royalty • Research and Development agreement with British American Tobacco Lexaria Pharmaceutical Corp. (Wholly-Owned) • Proven delivery effectiveness in antiviral therapies for COVID-19/SARS-CoV-2 and other infectious diseases such as HIV, HSV, Influenza, EBV, HEP, CMV Lexaria Hemp Corp. (Wholly-Owned) • Clinically proven to increase rate and extent of orally ingested CBD (https://www.ncbi.nlm.nih.gov/pubmed/31512143) • Established North American partnerships generating revenues from DehydraTECH technology John Docherty, M.Sc., President & Director • Specialist in development of drug delivery technologies • Former President and COO of Helix BioPharma Corp. (TSX: HBP) • Named inventor on multiple issued and pending patents • Pharmacologist and toxicologist Chris Bunka, Chairman & CEO • Launched several successful private and public companies since the late 1980’s • Extensive experience in the capital markets, corporate governance, M&A and finance • Named inventor on multiple patent innovations MANAGEMENT Majority Interest Minority Interest + INVESTOR CONTACT Phone: 250-765-6424 ext. 202 ir@lexariabioscience.com Disclaimer: This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi ties Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities avai lable on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This fact sheet is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease. All supporting information for this fact sheet can be found at www.lexariabioscience.com.